Trends in the real-world management of patients with active relapsing-remitting multiple sclerosis treated with natalizumab (TYSABRIW) in France: An analysis of the PMSI database over five years (2019–2023)

Trends in the real-world management of patients with active relapsing-remitting multiple sclerosis treated with natalizumab (TYSABRIW) in France: An analysis of the PMSI database over five years (2019–2023)

LE PAGE E, EMERY C, FRAVALO A, FAGNANI F, CLEMENT A